

Special Scientific Lecture 1

Chairperson

Cheol-Young Park
Sungkyunkwan University, Korea

Speaker

Ania Jastreboff
Yale University, USA



Ania Jastreboff

Yale University, USA

• Education

Period	Affiliation	Position
– 2012	Yale University Graduate School of Arts and Science	Ph.D.
– 2002	University of Maryland School of Medicine	M.D.
– 1998	Bucknell University	B.A.

• Affiliations / Experience

Period	Affiliation	Position
– 2023-Present	Yale Obesity Research Center	Director
– 2020-Present	Yale Center for Weight Management	Co-Director
– 2020-Present	Yale University, USA	Associate Professor
– 2014-2020	Yale University, USA	Assistant Professor
– 2011-2014	Yale University, USA	Instructor

• Committee Memberships

- The Obesity Society (TOS)
- American Association of Clinical Endocrinology (AACE)
- and American College of Endocrinology
- American Diabetes Association (ADA)
- The Endocrine Society
- Lawson Wilkins Pediatric Endocrine Society

• Publications

- Kahn SE, Deanfield JE, Jeppesen OK, Emerson SS, Boesgaard TW, Colhoun HM, Kushner RF, Lingvay I, Burguera B, Gajos G, Horn DB, Hramiak IM, Jastreboff AM, Kokkinos A, Maeng M, Matos ALSA, Tinahones FJ, Lincoff AM, Ryan DH; SELECT Trial Investigators. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. *Diabetes Care*. 2024 Aug 1;47(8):1350-1359. doi: 10.2337/dc24-0491. PMID: 38907683; PMCID: PMC11282386
- Lu Y, Liu Y, Jastreboff AM, Khera R, Ndumele CD, Rodriguez F, Watson KE, Krumholz HM. Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey. *Circ Cardiovasc Qual Outcomes*. 2024 Jan;17(1):e010640. doi: 10.1161/CIRCOUTCOMES.123.010640. Epub 2023 Nov 11. Erratum in: *Circ Cardiovasc Qual Outcomes*. 2024 Jan;17(1):e000126. doi: 10.1161/HCQ.000000000000126. PMID: 37950677; PMCID: PMC10782930
- Jastreboff AM, Kushner RF. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. *Annu Rev Med*. 2023 Jan 27;74:125-139. doi: 10.1146/annurev-med-043021-014919. PMID: 36706749
- Gossman M, Butsch WS, Jastreboff AM. Treating the Chronic Disease of Obesity. *Med Clin North Am*. 2021 Nov;105(6):983-1016. doi: 10.1016/j.mcna.2021.06.005. PMID: 34688422
- Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. *N Engl J Med*. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26. PMID: 37366315

Special Scientific Lecture 1

Nutrients-Stimulated Hormone-Based Pharmacotherapy for the Treatment of Obesity: Sparks from the Pipeline!

Ania Jastreboff (Yale University, USA)
